Dimethyltryptamine for major depressive disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 23 Sep 2022: Trial registered, NCT05553691
  2. 13 Dec 2022: Trial started, NCT05553691

The trials

NCT05553691: SPL026 With or Without SSRIs in Participants With MDD

State
Completed
Phase
Phase 1
People
18 taking part
Started
13 Dec 2022
Primary completion
3 Aug 2023
Arms
Test Cohort, Control Cohort
Results
None posted
  1. 23 Sep 2022: Trial registered
  2. 13 Dec 2022: Trial started
  3. 3 Aug 2023: Trial completed

NCT06927076: Antidepressant Response of DMT Masked With Propofol

State
Under way
Phase
No phase
People
112 planned
Started
5 Aug 2025
Primary completion
Mar 2029
Arms
DMT without sedation, DMT with sedation
Results
None posted
  1. 15 Apr 2025: Trial registered
  2. 5 Aug 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as N,N-Dimethyltryptamine, SPL026.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.